Skip Navigation

This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Antman, A.M.
Right arrow Articles by Braunwald, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Antman, A.M.
Right arrow Articles by Braunwald, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Epicardial flow and myocardial reperfusion following abciximab and low-dose thrombolytic therapy for acute myocardial infarction

A.M. Antman, J.A. de Lemos and E. Braunwald1

Harvard Medical School, Brigham and Women's Hospital, Boston MA, U.S.A.

1 Correspondence: Eugene Braunwald, MD, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, U.S.A.

Abstract

Recent evidence from the Thrombolysis in Myocardial Infarction (TIMI) 14 trial suggests that combining reduceddose fibrinolytic therapy with the potent platelet inhibition afforded by a glycoprotein (GP) IIb/IIIa receptor antagonist can help overcome the limitations of fibrinolytic therapy alone. The TIMI 14 investigators found that lowdose alteplase in combination with abciximab significantly increased the incidence of TIMI 3 flow at 60 and 90 min compared with full-dose alteplase. The use of abciximab emerged as one of the three principal determinants of TIMI 3 flow, along with time to treatment and location of the occlusive thrombus. Complete ST-segment resolution, reflecting perfusion at the myocardial tissue level, was a significant predictor of 30-day survival in the TIMI 14 study. Patients treated with abciximab plus reduced-dose fibrinolytic therapy had significantly greater median ST-segment resolution and a significantly higher rate of complete ST-segment resolution than patients given fibrinolytic therapy alone. Similar benefits were observed in TIMI 14 patients who underwent early adjunctive percutaneous coronary intervention following combined therapy with abciximab and reduced-dose fibrinolysis. These findings indicate that a strategy coupling abciximab with reduceddose fibrinolytic therapy not only enhances epicardial flow but also improves myocardial reperfusion following acute myocardial infarction.

Key Words: Abciximab • GP IIb/IIIa receptor • TIMI 14 • perfusion • microvascular • ST-segment resolution

References

  1. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronaryartery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615–1622GUSTO Angiographic Investigators. Erratum. N Engl J Med. 1994;330:516[Free Full Text]
  2. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and frontloaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation. 1996;94:891–898[Abstract/Free Full Text]
  3. Cannon CP, McCabe CH, Diver DJ, et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolysic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol. 1994;24:1602–1610[Abstract]
  4. Jang IK, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator: a possible explanation for resistance to coronary thrombolysis. Circulation. 1989;79:920–928[Abstract/Free Full Text]
  5. Rasmanis G, Vesterqvist O, Green K, Edhag O, Henriksson P. Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction. Br Heart J. 1992;68:374–376[Abstract/Free Full Text]
  6. Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. J Am Coll Cardiol. 1998;31:1466–1473[Abstract/Free Full Text]
  7. Gertz SD, Kragel AH, Kalan JM, Braunwald E, Roberts WC. Comparison of coronary and myocardial morphologic findings in patients with and without thrombolytic therapy during fatal first acute myocardial infarction. The TIMI Investigators. Am J Cardiol. 1990;66:904–909[CrossRef][Web of Science][Medline]
  8. Cannon CP. Overcoming thrombolytic resistance: rationale and initial clinical experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol. 1999;34:1395–1402[Abstract/Free Full Text]
  9. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553–1559[Free Full Text]
  10. Yasuda T, Gold HK, Leinbach RC, et al. Lysis of plasminogen activator-resistant platelet-rich coronary artery thrombus with combined bolus injection of recombinant tissue-type plasminogen activator and antiplatelet GPIIb/IIIa antibody. J Am Coll Cardiol. 1990;16:1728–1735[Abstract]
  11. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 pilot study. J Am Coll Cardiol. 1993;22:381–389[Abstract]
  12. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial. Circulation. 1999;99:2720–2732[Abstract/Free Full Text]
  13. Antman EM, Gibson CM, de Lemos JA, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. Eur Heart J. 2000;21:1944–1953[Abstract/Free Full Text]
  14. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Circulation. 2000;101:2788–2794[Abstract/Free Full Text]
  15. Smalling RW, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation. 1995;91:2725–2732[Abstract/Free Full Text]
  16. Ito H, Iwakura K, Oh H, et al. Temporal changes in myocardial perfusion patterns in patients with reperfased anterior wall myocardial infarction: their relation to myocardial viability. Circulation. 1995;91:656–662[Abstract/Free Full Text]
  17. Gassler JP, Topol EJ. Reperfasion revisited: beyond TIMI 3 flow. Clin Cardiol. 1999;22(Suppl IV[):IV-20–IV-29[Medline]
  18. Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation. 1996;93:1993–1999[Abstract/Free Full Text]
  19. Zeymer U, Tebbe U, Sadowski Z, et al. ST resolution at 90 and 180 minutes in patients with acute myocardial infarction treated with lanoteplase or alteplase: results of the InTIME-2 ECG ST resolution substudy. (Abstr)Eur Heart J. 2000;21:137 (Suppl)[Abstract/Free Full Text]
  20. de Lemos JA, Antman EM, Giugliano RP, et al, InTIME II Investigators. Very early risk stratification after thrombolytic therapy using a bedside myoglobin assay and the 12-lead ECG. Am Heart J. 2000;140:373–378[CrossRef][Web of Science][Medline]
  21. de Lemos JA, Antman EM, Giugliano RP, et al. ST-segment resolution and infarct-related artery patency and flow after thrombolytic therapy. Am J Cardiol. 2000;85:299–304[CrossRef][Web of Science][Medline]
  22. Schroder R, Wegscheider K, Schroder K, Dissmann R, Meyer-Sabellek W. Extent of early ST segment elevation resolution: a strong predictor of outcome in patients with acute myocardial infarction and a sensitive measure to compare thrombolytic regimens. A substudy of the International Joint Efficacy Comparison of Thrombolytics (INJECT) trial. J Am Coll Cardiol. 1995;26:1657–1664[Abstract]
  23. de Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction: observations from the TIMI 14 trial. Circulation. 2000;101:239–243[Abstract/Free Full Text]
  24. de Lemos JA, Gibson CM, Antman EM, et al. Abciximab improves microvascular function after rescue PCI: a TIMI 14 substudy. (Abstr)J Am Coll Cardiol. 2000;35(Suppl A):47A
  25. Gibson M, Cannon CP, Murphy SA, et al. A new angiographic method to assess myocardial perfusion and its relationship to mortality following thrombolytic administration: the TIMI Myocardial Perfusion Grade. (Abstr)Circulation. 1999;100(Suppl I):I–791

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?



This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Antman, A.M.
Right arrow Articles by Braunwald, E.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Antman, A.M.
Right arrow Articles by Braunwald, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?